Pharmaniaga Continues To Explore Overseas Sinovac Supply

Pharmaniaga Bhd is looking at expanding its presence in Southeast Asia and the African markets for the supply of Sinovac finished vaccines manufactured in its high-tech plant.

Pharmaniaga Group Managing Director Datuk Zulkarnain Md Eusope says with a population of more than 700 million in the Southeast Asia region and a 1.3 billion population in the African continent, the company sees tremendous potential for growth of its overseas operations.

“Following our completion of distributing and supplying Sinovac COVID-19 vaccine to the Federal Government totalling 20.4 million doses, we are looking at further opportunities to export the vaccine overseas.

“Currently, we are in the midst of a discussion with Sinovac Life Sciences Co., Ltd. to facilitate the export of the vaccine to countries that face challenges in securing sufficient supply in various Southeast Asian countries as well as several African nations. Thus, this planning has allowed the Group to capitalise on these apt opportunities.

“Although there will be tough competition, we are focused on improving our operations in order to capture the immense potential in these countries,” he says.

Following the recent approval from the National Pharmaceutical Regulatory Agency, the Group will continue production of the fill and finish Sinovac COVID-19 vaccine at its wholly-owned subsidiary high-tech plant, Pharmaniaga LifeScience Sdn Bhd, says Zulkarnain.

Previous articleROC Oil Sarawak Awards RM4.7 Million Drilling Concession To Reservoir Link
Next articlePlus Solar Rebrands And Offers Unique Rent To Own Program For House Owners

LEAVE A REPLY

Please enter your comment!
Please enter your name here